Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion (BMEA) with an Overweight rating and $7 price target The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: